Mirjam Stahl1,2,3, Mark O Wielpütz4,3,5, Simon Y Graeber1,2,3, Cornelia Joachim1,2,3, Olaf Sommerburg1,2,3, Hans-Ulrich Kauczor4,3, Michael Puderbach5,6, Monika Eichinger3,5,6, Marcus A Mall1,2,3. 1. 1 Department of Translational Pulmonology. 2. 2 Division of Pediatric Pulmonology and Allergy and Cystic Fibrosis Center, Department of Pediatrics, and. 3. 3 Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany. 4. 4 Department of Diagnostic and Interventional Radiology, University of Heidelberg, Heidelberg, Germany. 5. 5 Department of Radiology, German Cancer Research Center, Heidelberg, Germany; and. 6. 6 Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany.
Abstract
RATIONALE: Early onset and progression of lung disease in children with cystic fibrosis (CF) indicates that sensitive noninvasive outcome measures are needed for diagnostic monitoring and early intervention clinical trials. The lung clearance index (LCI) and chest magnetic resonance imaging (MRI) were shown to detect early lung disease in CF; however, the relationship between the two measures remains unknown. OBJECTIVES: To correlate the LCI with abnormalities detected by MRI and compare the sensitivity of the two techniques to detect responses to therapy for pulmonary exacerbations in children with CF. METHODS: LCI determined by age-adapted multiple breath washout techniques and MRI studies were performed in 97 clinically stable children with CF across the pediatric age range (0.2-21.1 yr). Furthermore, LCI (n = 26) or MRI (n = 10) were performed at the time of pulmonary exacerbation and after antibiotic therapy. MRI was evaluated using a dedicated morphofunctional score. MEASUREMENTS AND MAIN RESULTS: The LCI correlated with the global MRI score as well as MRI-defined airway wall abnormalities, mucus plugging, and abnormal lung perfusion in infants and toddlers (P < 0.05 to P < 0.001) and in older children (P < 0.001) with CF. LCI and MRI were sensitive to detect response to antibiotic therapy for pulmonary exacerbations. CONCLUSIONS: Our results indicate that LCI and MRI may be useful complementary tools for noninvasive monitoring and as quantitative endpoints in early intervention trials in children with CF. In this context, MRI enables detection of disease heterogeneity, including regional mucus plugging associated with abnormal lung perfusion in early CF lung disease. Clinical trial registered with www.clinicaltrials.gov (NCT 02270476).
RATIONALE: Early onset and progression of lung disease in children with cystic fibrosis (CF) indicates that sensitive noninvasive outcome measures are needed for diagnostic monitoring and early intervention clinical trials. The lung clearance index (LCI) and chest magnetic resonance imaging (MRI) were shown to detect early lung disease in CF; however, the relationship between the two measures remains unknown. OBJECTIVES: To correlate the LCI with abnormalities detected by MRI and compare the sensitivity of the two techniques to detect responses to therapy for pulmonary exacerbations in children with CF. METHODS:LCI determined by age-adapted multiple breath washout techniques and MRI studies were performed in 97 clinically stable children with CF across the pediatric age range (0.2-21.1 yr). Furthermore, LCI (n = 26) or MRI (n = 10) were performed at the time of pulmonary exacerbation and after antibiotic therapy. MRI was evaluated using a dedicated morphofunctional score. MEASUREMENTS AND MAIN RESULTS: The LCI correlated with the global MRI score as well as MRI-defined airway wall abnormalities, mucus plugging, and abnormal lung perfusion in infants and toddlers (P < 0.05 to P < 0.001) and in older children (P < 0.001) with CF. LCI and MRI were sensitive to detect response to antibiotic therapy for pulmonary exacerbations. CONCLUSIONS: Our results indicate that LCI and MRI may be useful complementary tools for noninvasive monitoring and as quantitative endpoints in early intervention trials in children with CF. In this context, MRI enables detection of disease heterogeneity, including regional mucus plugging associated with abnormal lung perfusion in early CF lung disease. Clinical trial registered with www.clinicaltrials.gov (NCT 02270476).
Authors: Patricia Leutz-Schmidt; Monika Eichinger; Mirjam Stahl; Olaf Sommerburg; Jürgen Biederer; Hans-Ulrich Kauczor; Michael U Puderbach; Marcus A Mall; Mark O Wielpütz Journal: Radiologe Date: 2019-12 Impact factor: 0.635
Authors: Marcus J Couch; Robert Thomen; Nikhil Kanhere; Raymond Hu; Felix Ratjen; Jason Woods; Giles Santyr Journal: J Cyst Fibros Date: 2019-03-25 Impact factor: 5.482
Authors: Robert P Thomen; Laura L Walkup; David J Roach; Nara Higano; Andrew Schapiro; Alan Brody; John P Clancy; Zackary I Cleveland; Jason C Woods Journal: Am J Respir Crit Care Med Date: 2020-07-15 Impact factor: 21.405
Authors: Sanja Stanojevic; Stephanie D Davis; George Retsch-Bogart; Hailey Webster; Miriam Davis; Robin C Johnson; Renee Jensen; Maria Ester Pizarro; Mica Kane; Charles C Clem; Leah Schornick; Padmaja Subbarao; Felix A Ratjen Journal: Am J Respir Crit Care Med Date: 2017-05-01 Impact factor: 21.405
Authors: Eric W F W Alton; A Christopher Boyd; Jane C Davies; Deborah R Gill; Uta Griesenbach; Tracy E Harman; Stephen Hyde; Gerry McLachlan Journal: Hum Gene Ther Date: 2020-09 Impact factor: 5.695
Authors: Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen Journal: Lancet Respir Med Date: 2019-09-27 Impact factor: 30.700